<?xml version="1.0" encoding="utf-8"?> 
<rss version="2.0">
	<channel>
		<title>GIST In the News</title>
		<link>http://gistsupport.org</link>
		<description> GIST Support International is a support group of patients and families affected by gastrointestinal stromal tumor.  GIST Support International is dedicated to education and support of GIST patients and families and friends.</description>
		<language>en</language>
		<copyright>Copyright 2013, GIST Support International</copyright>
		<managingEditor>admin@yourdomain.com</managingEditor>
		<webMaster>admin@yourdomain.com</webMaster>
		<category>GIST Support International</category>
		<generator>WebsiteBaker Content Management System</generator>
	<item>
		<title><![CDATA[Ponatinib trial opens]]></title>
		<description><![CDATA[<p>phase II trial in GIST</p>]]></description>
		<link>http://www.gistsupport.org/posts/ponatinib-trial-opens-211.php</link>
		<pubDate>Tue, 11 Jun 2013</pubDate>
		<guid>http://www.gistsupport.org/posts/ponatinib-trial-opens-211.php</guid>
	</item>
	<item>
		<title><![CDATA[Project FLAG]]></title>
		<description><![CDATA[<p>Enrollment complete, information available.</p>]]></description>
		<link>http://www.gistsupport.org/posts/project-flag-136.php</link>
		<pubDate>Thu, 23 Jul 2009</pubDate>
		<guid>http://www.gistsupport.org/posts/project-flag-136.php</guid>
	</item>
	<item>
		<title><![CDATA[Regorafenib Approved]]></title>
		<description><![CDATA[<p>Approved for&nbsp;GIST by FDA</p>]]></description>
		<link>http://www.gistsupport.org/posts/regorafenib-approved-204.php</link>
		<pubDate>Tue, 26 Feb 2013</pubDate>
		<guid>http://www.gistsupport.org/posts/regorafenib-approved-204.php</guid>
	</item>
	<item>
		<title><![CDATA[St. Louis GIST meeting]]></title>
		<description><![CDATA[<p>for patients and caregivers</p>]]></description>
		<link>http://www.gistsupport.org/posts/st.-louis-gist-meeting-206.php</link>
		<pubDate>Tue, 25 Sep 2012</pubDate>
		<guid>http://www.gistsupport.org/posts/st.-louis-gist-meeting-206.php</guid>
	</item>
	<item>
		<title><![CDATA[GIST News from ASCO]]></title>
		<description><![CDATA[<p>Our reps report on American Society for Clinical Oncology</p>]]></description>
		<link>http://www.gistsupport.org/posts/gist-news-from-asco-202.php</link>
		<pubDate>Tue, 19 Jun 2012</pubDate>
		<guid>http://www.gistsupport.org/posts/gist-news-from-asco-202.php</guid>
	</item>
	<item>
		<title><![CDATA[Aurora kinase A in GIST]]></title>
		<description><![CDATA[<p>risk marker and potential drug target</p>]]></description>
		<link>http://www.gistsupport.org/posts/aurora-kinase-a-in-gist-201.php</link>
		<pubDate>Tue, 29 May 2012</pubDate>
		<guid>http://www.gistsupport.org/posts/aurora-kinase-a-in-gist-201.php</guid>
	</item>
	<item>
		<title><![CDATA[Votrient approved for sarcoma]]></title>
		<description><![CDATA[<p>FDA approval or non-GIST soft tissue sarcoma</p>]]></description>
		<link>http://www.gistsupport.org/posts/votrient-approved-for-sarcoma-199.php</link>
		<pubDate>Thu, 22 Mar 2012</pubDate>
		<guid>http://www.gistsupport.org/posts/votrient-approved-for-sarcoma-199.php</guid>
	</item>
	<item>
		<title><![CDATA[FDA approves adjuvant Gleevec extension to 3 years]]></title>
		<description><![CDATA[<p>Longer duration for post-surgery Gleevec in higher-risk patients</p>]]></description>
		<link>http://www.gistsupport.org/posts/fda-approves-adjuvant-gleevec-extension-to-3-years-198.php</link>
		<pubDate>Fri, 03 Feb 2012</pubDate>
		<guid>http://www.gistsupport.org/posts/fda-approves-adjuvant-gleevec-extension-to-3-years-198.php</guid>
	</item>
	<item>
		<title><![CDATA[Free GIST Wristbands (bracelets)]]></title>
		<description><![CDATA[<p>from GCAF and GSI</p>]]></description>
		<link>http://www.gistsupport.org/posts/free-gist-wristbands-bracelets-195.php</link>
		<pubDate>Mon, 03 Oct 2011</pubDate>
		<guid>http://www.gistsupport.org/posts/free-gist-wristbands-bracelets-195.php</guid>
	</item>
	<item>
		<title><![CDATA[GIST News from 2011 ASCO]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/gist-news-from-2011-asco-190.php</link>
		<pubDate>Wed, 13 Jul 2011</pubDate>
		<guid>http://www.gistsupport.org/posts/gist-news-from-2011-asco-190.php</guid>
	</item>
	<item>
		<title><![CDATA[Italians Hold 4th GIST Meeting]]></title>
		<description><![CDATA[<p>Patients gather in Milan.</p>]]></description>
		<link>http://www.gistsupport.org/posts/italians-hold-4th-gist-meeting-187.php</link>
		<pubDate>Sun, 06 Mar 2011</pubDate>
		<guid>http://www.gistsupport.org/posts/italians-hold-4th-gist-meeting-187.php</guid>
	</item>
	<item>
		<title><![CDATA[Living With GIST: 10 Years of Molecularly Targeted Therapy]]></title>
		<description><![CDATA[<p>Watch videos from Dana-Farber's April 2010 event.</p>]]></description>
		<link>http://www.gistsupport.org/posts/living-with-gist-10-years-of-molecularly-targeted-therapy-180.php</link>
		<pubDate>Sat, 01 May 2010</pubDate>
		<guid>http://www.gistsupport.org/posts/living-with-gist-10-years-of-molecularly-targeted-therapy-180.php</guid>
	</item>
	<item>
		<title><![CDATA[ESMO GIST Guidelines]]></title>
		<description><![CDATA[<p>free access online</p>]]></description>
		<link>http://www.gistsupport.org/posts/esmo-gist-guidelines-183.php</link>
		<pubDate>Tue, 06 Jul 2010</pubDate>
		<guid>http://www.gistsupport.org/posts/esmo-gist-guidelines-183.php</guid>
	</item>
	<item>
		<title><![CDATA[ASCO 2010 News on GIST]]></title>
		<description><![CDATA[<p>Becky and Carolyn report for GIST Support International</p>]]></description>
		<link>http://www.gistsupport.org/posts/asco-2010-news-on-gist-182.php</link>
		<pubDate>Fri, 25 Jun 2010</pubDate>
		<guid>http://www.gistsupport.org/posts/asco-2010-news-on-gist-182.php</guid>
	</item>
	<item>
		<title><![CDATA[NCCN GIST Task Force Update]]></title>
		<description><![CDATA[<p>2010 recommendations from experts</p>]]></description>
		<link>http://www.gistsupport.org/posts/nccn-gist-task-force-update-181.php</link>
		<pubDate>Tue, 11 May 2010</pubDate>
		<guid>http://www.gistsupport.org/posts/nccn-gist-task-force-update-181.php</guid>
	</item>
	<item>
		<title><![CDATA[ESMO GIST meeting]]></title>
		<description><![CDATA[<p>state-of-the-art for GIST</p>]]></description>
		<link>http://www.gistsupport.org/posts/esmo-gist-meeting-177.php</link>
		<pubDate>Tue, 16 Mar 2010</pubDate>
		<guid>http://www.gistsupport.org/posts/esmo-gist-meeting-177.php</guid>
	</item>
	<item>
		<title><![CDATA[Sarcoma Awareness Week]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/sarcoma-awareness-week-171.php</link>
		<pubDate>Sat, 06 Feb 2010</pubDate>
		<guid>http://www.gistsupport.org/posts/sarcoma-awareness-week-171.php</guid>
	</item>
	<item>
		<title><![CDATA[578 Signed R1507 Petition]]></title>
		<description><![CDATA[<p>supporting trial for pediatric &amp; wildtype GIST</p>]]></description>
		<link>http://www.gistsupport.org/posts/578-signed-r1507-petition-170.php</link>
		<pubDate>Sat, 28 Nov 2009</pubDate>
		<guid>http://www.gistsupport.org/posts/578-signed-r1507-petition-170.php</guid>
	</item>
	<item>
		<title><![CDATA[GIST at 2009 ASCO]]></title>
		<description><![CDATA[<p>Access videos and webcasts from the meeting.</p>]]></description>
		<link>http://www.gistsupport.org/posts/gist-at-2009-asco-163.php</link>
		<pubDate>Sat, 30 May 2009</pubDate>
		<guid>http://www.gistsupport.org/posts/gist-at-2009-asco-163.php</guid>
	</item>
	<item>
		<title><![CDATA[Sunitinib approved in UK]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/sunitinib-approved-in-uk162.php</link>
		<pubDate>Fri, 29 May 2009</pubDate>
		<guid>http://www.gistsupport.org/posts/sunitinib-approved-in-uk162.php</guid>
	</item>
	<item>
		<title><![CDATA[GIST Management 2009 Update]]></title>
		<description><![CDATA[report from CME lectures ]]></description>
		<link>http://www.gistsupport.org/posts/gist-management-2009-update157.php</link>
		<pubDate>Wed, 13 May 2009</pubDate>
		<guid>http://www.gistsupport.org/posts/gist-management-2009-update157.php</guid>
	</item>
	<item>
		<title><![CDATA[Attending a GIST CME Event]]></title>
		<description><![CDATA[Patients make a difference! ]]></description>
		<link>http://www.gistsupport.org/posts/attending-a-gist-cme-event158.php</link>
		<pubDate>Wed, 13 May 2009</pubDate>
		<guid>http://www.gistsupport.org/posts/attending-a-gist-cme-event158.php</guid>
	</item>
	<item>
		<title><![CDATA[Adjuvant Imatinib in Europe]]></title>
		<description><![CDATA[EC approves post-surgery imatinib ]]></description>
		<link>http://www.gistsupport.org/posts/adjuvant-imatinib-in-europe161.php</link>
		<pubDate>Sat, 09 May 2009</pubDate>
		<guid>http://www.gistsupport.org/posts/adjuvant-imatinib-in-europe161.php</guid>
	</item>
	<item>
		<title><![CDATA[IGF signals in GIST]]></title>
		<description><![CDATA[Insulin-related growth factor family: potential role in GIST ]]></description>
		<link>http://www.gistsupport.org/posts/igf-signals-in-gist134.php</link>
		<pubDate>Fri, 30 Jan 2009</pubDate>
		<guid>http://www.gistsupport.org/posts/igf-signals-in-gist134.php</guid>
	</item>
	<item>
		<title><![CDATA[Sorafenib Is Promising]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/sorafenib-is-promising117.php</link>
		<pubDate>Mon, 12 Jan 2009</pubDate>
		<guid>http://www.gistsupport.org/posts/sorafenib-is-promising117.php</guid>
	</item>
	<item>
		<title><![CDATA[Sutent conditionally approved in EU]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/sutent-conditionally-approved-in-eu52.php</link>
		<pubDate>Tue, 06 Jan 2009</pubDate>
		<guid>http://www.gistsupport.org/posts/sutent-conditionally-approved-in-eu52.php</guid>
	</item>
	<item>
		<title><![CDATA[FDA Approves Adjuvant Imatinib]]></title>
		<description><![CDATA[to prevent GIST recurrence]]></description>
		<link>http://www.gistsupport.org/posts/fda-approves-adjuvant-imatinib155.php</link>
		<pubDate>Sat, 20 Dec 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/fda-approves-adjuvant-imatinib155.php</guid>
	</item>
	<item>
		<title><![CDATA[CTOS and SARC Meet in London]]></title>
		<description><![CDATA[Barbara Dore' attends for GIST Support International ]]></description>
		<link>http://www.gistsupport.org/posts/ctos-and-sarc-meet-in-london149.php</link>
		<pubDate>Fri, 05 Dec 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/ctos-and-sarc-meet-in-london149.php</guid>
	</item>
	<item>
		<title><![CDATA[NIH Clinic for Ped & Wildtype GIST]]></title>
		<description><![CDATA[expansion to include wildtype GIST adults]]></description>
		<link>http://www.gistsupport.org/posts/nih-clinic-for-ped-wildtype-gist148.php</link>
		<pubDate>Wed, 26 Nov 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/nih-clinic-for-ped-wildtype-gist148.php</guid>
	</item>
	<item>
		<title><![CDATA[Duensing's New GIST Findings]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/duensings-new-gist-findings147.php</link>
		<pubDate>Tue, 18 Nov 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/duensings-new-gist-findings147.php</guid>
	</item>
	<item>
		<title><![CDATA[NIH Pediatric GIST Clinic]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/nih-pediatric-gist-clinic125.php</link>
		<pubDate>Sun, 26 Oct 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/nih-pediatric-gist-clinic125.php</guid>
	</item>
	<item>
		<title><![CDATA[Adjuvant Gleevec Trial News]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/adjuvant-gleevec-trial-news68.php</link>
		<pubDate>Fri, 17 Oct 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/adjuvant-gleevec-trial-news68.php</guid>
	</item>
	<item>
		<title><![CDATA[Z9000 Adjuvant Imatinib Trial]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/z9000-adjuvant-imatinib-trial118.php</link>
		<pubDate>Fri, 17 Oct 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/z9000-adjuvant-imatinib-trial118.php</guid>
	</item>
	<item>
		<title><![CDATA[ESMO GIST Session]]></title>
		<description><![CDATA[9 expert presentations ]]></description>
		<link>http://www.gistsupport.org/posts/esmo-gist-session138.php</link>
		<pubDate>Tue, 15 Jul 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/esmo-gist-session138.php</guid>
	</item>
	<item>
		<title><![CDATA[New Italian GIST group]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/new-italian-gist-group59.php</link>
		<pubDate>Sun, 29 Jun 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/new-italian-gist-group59.php</guid>
	</item>
	<item>
		<title><![CDATA[Treating GIST]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/treating-gist114.php</link>
		<pubDate>Sat, 14 Jun 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/treating-gist114.php</guid>
	</item>
	<item>
		<title><![CDATA[Plasma Imatinib Levels]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/plasma-imatinib-levels116.php</link>
		<pubDate>Tue, 27 May 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/plasma-imatinib-levels116.php</guid>
	</item>
	<item>
		<title><![CDATA[Sarcoma Video]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/sarcoma-video71.php</link>
		<pubDate>Thu, 28 Feb 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/sarcoma-video71.php</guid>
	</item>
	<item>
		<title><![CDATA[Attention for GI Cancers]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/attention-for-gi-cancers115.php</link>
		<pubDate>Sat, 02 Feb 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/attention-for-gi-cancers115.php</guid>
	</item>
	<item>
		<title><![CDATA[Nilotinib Compassionate Access Ends]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/nilotinib-compassionate-access-ends113.php</link>
		<pubDate>Sun, 20 Jan 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/nilotinib-compassionate-access-ends113.php</guid>
	</item>
	<item>
		<title><![CDATA[Sunitinib & Heart Failure]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/sunitinib-heart-failure112.php</link>
		<pubDate>Fri, 18 Jan 2008</pubDate>
		<guid>http://www.gistsupport.org/posts/sunitinib-heart-failure112.php</guid>
	</item>
	<item>
		<title><![CDATA[2007 NCCN Task Force on GIST]]></title>
		<description><![CDATA[updated GIST guidelines, related webcast... ]]></description>
		<link>http://www.gistsupport.org/posts/2007-nccn-task-force-on-gist100.php</link>
		<pubDate>Sun, 09 Sep 2007</pubDate>
		<guid>http://www.gistsupport.org/posts/2007-nccn-task-force-on-gist100.php</guid>
	</item>
	<item>
		<title><![CDATA[GIST featured at MDA]]></title>
		<description><![CDATA[MD Anderson newsletter <em>CancerWise</em> ]]></description>
		<link>http://www.gistsupport.org/posts/gist-featured-at-mda99.php</link>
		<pubDate>Thu, 02 Aug 2007</pubDate>
		<guid>http://www.gistsupport.org/posts/gist-featured-at-mda99.php</guid>
	</item>
	<item>
		<title><![CDATA[World Congress on Gastrointestinal Cancer]]></title>
		<description><![CDATA[<p>World Congress on Gastrointestinal Cancer (Webcasts)</p>]]></description>
		<link>http://www.gistsupport.org/posts/world-congress-on-gastrointestinal-cancer39.php</link>
		<pubDate>Thu, 02 Aug 2007</pubDate>
		<guid>http://www.gistsupport.org/posts/world-congress-on-gastrointestinal-cancer39.php</guid>
	</item>
	<item>
		<title><![CDATA[Predicting Side Effects]]></title>
		<description><![CDATA[downloadable calculator to predict side effects of imatinib (Gleevec)]]></description>
		<link>http://www.gistsupport.org/posts/predicting-side-effects88.php</link>
		<pubDate>Thu, 26 Jul 2007</pubDate>
		<guid>http://www.gistsupport.org/posts/predicting-side-effects88.php</guid>
	</item>
	<item>
		<title><![CDATA[GSI Signs Bad Nauheim Declaration]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/gsi-signs-bad-nauheim-declaration87.php</link>
		<pubDate>Mon, 23 Jul 2007</pubDate>
		<guid>http://www.gistsupport.org/posts/gsi-signs-bad-nauheim-declaration87.php</guid>
	</item>
	<item>
		<title><![CDATA[Bike Tour Funds Awarded]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/bike-tour-funds-awarded57.php</link>
		<pubDate>Tue, 03 Jul 2007</pubDate>
		<guid>http://www.gistsupport.org/posts/bike-tour-funds-awarded57.php</guid>
	</item>
	<item>
		<title><![CDATA[Team Sarcoma 2007]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/team-sarcoma-200769.php</link>
		<pubDate>Thu, 14 Jun 2007</pubDate>
		<guid>http://www.gistsupport.org/posts/team-sarcoma-200769.php</guid>
	</item>
	<item>
		<title><![CDATA[Do Not Interrupt Gleevec]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/do-not-interrupt-gleevec72.php</link>
		<pubDate>Sun, 13 May 2007</pubDate>
		<guid>http://www.gistsupport.org/posts/do-not-interrupt-gleevec72.php</guid>
	</item>
	<item>
		<title><![CDATA[HSP90 inhibitor progress]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/hsp90-inhibitor-progress67.php</link>
		<pubDate>Mon, 12 Mar 2007</pubDate>
		<guid>http://www.gistsupport.org/posts/hsp90-inhibitor-progress67.php</guid>
	</item>
	<item>
		<title><![CDATA[Free-access GIST reviews]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/free-access-gist-reviews66.php</link>
		<pubDate>Fri, 23 Feb 2007</pubDate>
		<guid>http://www.gistsupport.org/posts/free-access-gist-reviews66.php</guid>
	</item>
	<item>
		<title><![CDATA[CancerCare GIST teleconference]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/cancercare-gist-teleconference64.php</link>
		<pubDate>Sun, 04 Feb 2007</pubDate>
		<guid>http://www.gistsupport.org/posts/cancercare-gist-teleconference64.php</guid>
	</item>
	<item>
		<title><![CDATA[Sutent and Thyroid Function]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/sutent-and-thyroid-function62.php</link>
		<pubDate>Thu, 11 Jan 2007</pubDate>
		<guid>http://www.gistsupport.org/posts/sutent-and-thyroid-function62.php</guid>
	</item>
	<item>
		<title><![CDATA[GIST Summit webcasts]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/gist-summit-webcasts63.php</link>
		<pubDate>Tue, 02 Jan 2007</pubDate>
		<guid>http://www.gistsupport.org/posts/gist-summit-webcasts63.php</guid>
	</item>
	<item>
		<title><![CDATA[Cardiotoxicity from imatinib?]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/cardiotoxicity-from-imatinib53.php</link>
		<pubDate>Mon, 04 Dec 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/cardiotoxicity-from-imatinib53.php</guid>
	</item>
	<item>
		<title><![CDATA[ Slide presentation from Dr. Peter Reichardt]]></title>
		<description><![CDATA[Dr. Peter Reichardt has generously made available the slides he used at his June 2005 presentation at the meeting &quot;New Horizons in Treating Cancer: Third International Conference for Organizations Representing People with CML or GIST,&quot; held in Dublin, Ireland. This presentation summarizes the consensus about GIST diagnosis and treatment from the European Society of Medical Oncology and also summarizes current GIST drug research. This is a pdf file that can be viewed using Adobe Reader (a free program). ]]></description>
		<link>http://www.gistsupport.org/posts/slide-presentation-from-dr.-peter-reichardt15.php</link>
		<pubDate>Sun, 19 Nov 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/slide-presentation-from-dr.-peter-reichardt15.php</guid>
	</item>
	<item>
		<title><![CDATA[Managing Sutent side effects]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/managing-sutent-side-effects61.php</link>
		<pubDate>Sat, 28 Oct 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/managing-sutent-side-effects61.php</guid>
	</item>
	<item>
		<title><![CDATA[Warning: Gleevec heart effects]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/warning-gleevec-heart-effects58.php</link>
		<pubDate>Fri, 20 Oct 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/warning-gleevec-heart-effects58.php</guid>
	</item>
	<item>
		<title><![CDATA[Dr. von Mehren on GIST]]></title>
		<description><![CDATA[<p />]]></description>
		<link>http://www.gistsupport.org/posts/dr.-von-mehren-on-gist55.php</link>
		<pubDate>Sat, 23 Sep 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/dr.-von-mehren-on-gist55.php</guid>
	</item>
	<item>
		<title><![CDATA[PET Scans & Medicare]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/pet-scans-medicare54.php</link>
		<pubDate>Fri, 25 Aug 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/pet-scans-medicare54.php</guid>
	</item>
	<item>
		<title><![CDATA[GSI attends ASCO]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/gsi-attends-asco51.php</link>
		<pubDate>Wed, 21 Jun 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/gsi-attends-asco51.php</guid>
	</item>
	<item>
		<title><![CDATA[Sutent approved in Canada]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/sutent-approved-in-canada50.php</link>
		<pubDate>Thu, 01 Jun 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/sutent-approved-in-canada50.php</guid>
	</item>
	<item>
		<title><![CDATA[ Searchable online Canadian database of health product adverse reactions]]></title>
		<description><![CDATA[<p><br /></p>]]></description>
		<link>http://www.gistsupport.org/posts/searchable-online-canadian-database-of-health-product-adverse-reactions20.php</link>
		<pubDate>Fri, 26 May 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/searchable-online-canadian-database-of-health-product-adverse-reactions20.php</guid>
	</item>
	<item>
		<title><![CDATA[Novartis GIST Registry]]></title>
		<description><![CDATA[&nbsp;]]></description>
		<link>http://www.gistsupport.org/posts/novartis-gist-registry45.php</link>
		<pubDate>Wed, 24 May 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/novartis-gist-registry45.php</guid>
	</item>
	<item>
		<title><![CDATA[ESMO GIST/Sarcoma meeting]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/esmo-gistsarcoma-meeting49.php</link>
		<pubDate>Tue, 16 May 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/esmo-gistsarcoma-meeting49.php</guid>
	</item>
	<item>
		<title><![CDATA[Sarcoma Awareness Week]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/sarcoma-awareness-week48.php</link>
		<pubDate>Fri, 12 May 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/sarcoma-awareness-week48.php</guid>
	</item>
	<item>
		<title><![CDATA[Sunitinib advances in Europe]]></title>
		<description><![CDATA[]]></description>
		<link>http://www.gistsupport.org/posts/sunitinib-advances-in-europe46.php</link>
		<pubDate>Tue, 02 May 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/sunitinib-advances-in-europe46.php</guid>
	</item>
	<item>
		<title><![CDATA[Sutent benefits over half of trial patients]]></title>
		<description><![CDATA[Clinical trial shows SU11248 benefits more than half of patients with gastrointestinal tumors resistant to Gleevec.  This news story from Dana-Farber summarizes the Sutent study presented at ASCO 2005 (see our webcasts page). ]]></description>
		<link>http://www.gistsupport.org/posts/sutent-benefits-over-half-of-trial-patients9.php</link>
		<pubDate>Sun, 23 Apr 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/sutent-benefits-over-half-of-trial-patients9.php</guid>
	</item>
	<item>
		<title><![CDATA[Phase I Clinical Trial of IPI-504]]></title>
		<description><![CDATA[<p>This new drug is entering a Phase I trial at Dana Farber Cancer Center for patients with GIST who have progressed on Gleevec. Trial participants may have tried other drugs besides Gleevec. </p>]]></description>
		<link>http://www.gistsupport.org/posts/phase-i-clinical-trial-of-ipi-5048.php</link>
		<pubDate>Sun, 23 Apr 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/phase-i-clinical-trial-of-ipi-5048.php</guid>
	</item>
	<item>
		<title><![CDATA[4-year follow-up of Gleevec]]></title>
		<description><![CDATA[Saturday, February 04, 2006 ]]></description>
		<link>http://www.gistsupport.org/posts/4-year-follow-up-of-gleevec3.php</link>
		<pubDate>Sun, 23 Apr 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/4-year-follow-up-of-gleevec3.php</guid>
	</item>
	<item>
		<title><![CDATA[Sutent Approved for GIST]]></title>
		<description><![CDATA[As of 1/26/2006, Sutent (sunitinib malate, formerly known as SU11248) is approved for imatinib-resistant GIST patients. ]]></description>
		<link>http://www.gistsupport.org/posts/sutent-approved-for-gist7.php</link>
		<pubDate>Sun, 23 Apr 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/sutent-approved-for-gist7.php</guid>
	</item>
	<item>
		<title><![CDATA[Biology of Gastrointestinal Stromal Tumors -- Corless et al. 22 (18): 3813 -- Journal of Clinical Oncology]]></title>
		<description><![CDATA[<p><font size="-1">From the Oregon Health &amp; Science University Cancer Institute, Department of Pathology, and Division of Hematology and Oncology, Oregon Health &amp; Science University and Veterans Affairs Medical Center, Portland, OR; and Department of Pathology, Brigham &amp; Women's Hospital, Boston, MA</font></p>]]></description>
		<link>http://www.gistsupport.org/posts/biology-of-gastrointestinal-stromal-tumors--corless-et-al.-22-18-3813--journal-of-clinical-oncology37.php</link>
		<pubDate>Thu, 06 Apr 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/biology-of-gastrointestinal-stromal-tumors--corless-et-al.-22-18-3813--journal-of-clinical-oncology37.php</guid>
	</item>
	<item>
		<title><![CDATA[Study finds new designer drug is potent treatment for chronic myelogenous leukemia]]></title>
		<description><![CDATA[<p>This EurekAlert neww story indicates a trial of AMN107 is coming soon
for GIST. AMN107 is a followup to Gleevec being developed by Novartis.</p>
]]></description>
		<link>http://www.gistsupport.org/posts/study-finds-new-designer-drug-is-potent-treatment-for-chronic-myelogenous-leukemia26.php</link>
		<pubDate>Fri, 17 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/study-finds-new-designer-drug-is-potent-treatment-for-chronic-myelogenous-leukemia26.php</guid>
	</item>
	<item>
		<title><![CDATA[FDA Works to Speed the Advent of New, More Effective Personalized Medicines]]></title>
		<description><![CDATA[<p>As part of an agency-wide initiative to speed development of new medical products through the science of pharmacogenomics, the Food and Drug Administration (FDA) today issued a final guidance titled &quot;Pharmacogenomic Data Submissions.&quot;</p>]]></description>
		<link>http://www.gistsupport.org/posts/fda-works-to-speed-the-advent-of-new-more-effective-personalized-medicines24.php</link>
		<pubDate>Thu, 16 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/fda-works-to-speed-the-advent-of-new-more-effective-personalized-medicines24.php</guid>
	</item>
	<item>
		<title><![CDATA[Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus Conference of 3/2004, under the auspices of ESMO]]></title>
		<description><![CDATA[<p>Below is an informal summary of a consensus summary on GIST treatment by an international group of GIST experts. The consensus conference to develop this guideline was sponsored by the European Society of Medical Oncology (ESMO) with a grant from Novartis. A meeting was held in March 2004 among 41 experts from 12 countries from around the world (not just Europe). The resulting paper was published in March 2005 in the Annals of Oncology, volume 16 pages 566-578. The paper is not free-access. This is a paper your oncologist should obtain and read. Its purpose is to continue in the path started by the NCCN guidelines (which it cites) to develop a standard of care for GIST.</p>]]></description>
		<link>http://www.gistsupport.org/posts/consensus-meeting-for-the-management-of-gastrointestinal-stromal-tumors-report-of-the-gist-consensus-conference-of-32004-under-the-auspices-of-esmo22.php</link>
		<pubDate>Thu, 16 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/consensus-meeting-for-the-management-of-gastrointestinal-stromal-tumors-report-of-the-gist-consensus-conference-of-32004-under-the-auspices-of-esmo22.php</guid>
	</item>
	<item>
		<title><![CDATA[Molecular Testing in Patients with Rare Cancer Predicts Response to Gleevec]]></title>
		<description><![CDATA[Dr. Michael Heinrich of Oregon Health Science University discusses how mutation testing can predict an individual GISTer's success with Gleevec. ]]></description>
		<link>http://www.gistsupport.org/posts/molecular-testing-in-patients-with-rare-cancer-predicts-response-to-gleevec21.php</link>
		<pubDate>Thu, 16 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/molecular-testing-in-patients-with-rare-cancer-predicts-response-to-gleevec21.php</guid>
	</item>
	<item>
		<title><![CDATA[The Implications of Kinase Mutations in Clinical Practice: An Interview on GIST With Dr. Michael Heinrich]]></title>
		<description><![CDATA[<p>This Medscape interview is free-access, but Medscape requires a simple user registration to view its content. </p>]]></description>
		<link>http://www.gistsupport.org/posts/the-implications-of-kinase-mutations-in-clinical-practice-an-interview-on-gist-with-dr.-michael-heinrich18.php</link>
		<pubDate>Thu, 16 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/the-implications-of-kinase-mutations-in-clinical-practice-an-interview-on-gist-with-dr.-michael-heinrich18.php</guid>
	</item>
	<item>
		<title><![CDATA[ Personalized Medicine Moves Forward]]></title>
		<description><![CDATA[This news release describes the applications of mutation testing to GIST patients, based on research by Dr. Heinrich at Oregon Health Science University. ]]></description>
		<link>http://www.gistsupport.org/posts/personalized-medicine-moves-forward17.php</link>
		<pubDate>Thu, 16 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/personalized-medicine-moves-forward17.php</guid>
	</item>
	<item>
		<title><![CDATA[CIW ENA 2004]]></title>
		<description><![CDATA[<p><a href="http://ex2.excerptamedica.com/ciw-04ena/index.cfm?fuseaction=CIS2002">CIW ENA 2004</a>: &quot;16th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'. &quot;</p>
]]></description>
		<link>http://www.gistsupport.org/posts/ciw-ena-200438.php</link>
		<pubDate>Mon, 13 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/ciw-ena-200438.php</guid>
	</item>
	<item>
		<title><![CDATA[A phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST)]]></title>
		<description><![CDATA[<p>Abstract of presentation by P Reichardt, D Pink, T Lindner, MC
Heinrich, P Cohen, Y Wang, A Tsyrlova, A Yap, S Dimitirijevic, CD Blanke<br />at the 2004 European Society for Medical Oncology congress  </p>
]]></description>
		<link>http://www.gistsupport.org/posts/a-phase-iii-trial-of-the-oral-pkc-inhibitor-pkc412-pkc-and-imatinib-mesylate-im-in-patients-pts-with-gastrointestinal-stromal-tumor-gist35.php</link>
		<pubDate>Mon, 13 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/a-phase-iii-trial-of-the-oral-pkc-inhibitor-pkc412-pkc-and-imatinib-mesylate-im-in-patients-pts-with-gastrointestinal-stromal-tumor-gist35.php</guid>
	</item>
	<item>
		<title><![CDATA[Lack of progression is the most clinically significant measure of a patient's clinical benefit...]]></title>
		<description><![CDATA[<p>Abstract of presentation by G Demetri, M von Mehren, H Joensuu, S
Finketstein, D Huse, B Kiese, K McDougal, S Dimitrijevic, GA
Glendenning, C Blanke at the 2004 European Society for Medical Oncology congress. </p>
]]></description>
		<link>http://www.gistsupport.org/posts/lack-of-progression-is-the-most-clinically-significant-measure-of-a-patients-clinical-benefit...33.php</link>
		<pubDate>Mon, 13 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/lack-of-progression-is-the-most-clinically-significant-measure-of-a-patients-clinical-benefit...33.php</guid>
	</item>
	<item>
		<title><![CDATA[ESMO: Tumor Shrinkage Doesn't Predict Response to Imatinib Therapy in Patients With Gastrointestinal Stromal Tumors]]></title>
		<description><![CDATA[<p style="color: rgb(0, 0, 0);"><font size="2" face="Arial, Helvetica, Sans Serif">VIENNA,
AUSTRIA -- November 4, 2004 -- Lack of progression is the most
clinically significant predictor of a patient's response to imatinib in
patients with gastrointestinal stromal tumours (GIST), a new analysis
shows.</font></p>
]]></description>
		<link>http://www.gistsupport.org/posts/esmo-tumor-shrinkage-doesnt-predict-response-to-imatinib-therapy-in-patients-with-gastrointestinal-stromal-tumors32.php</link>
		<pubDate>Mon, 13 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/esmo-tumor-shrinkage-doesnt-predict-response-to-imatinib-therapy-in-patients-with-gastrointestinal-stromal-tumors32.php</guid>
	</item>
	<item>
		<title><![CDATA[Tumor size alone not always best for gauging treatment response]]></title>
		<description><![CDATA[<p>Not only can positron emission tomography (PET) help evaluate treatment
for gastrointestinal stromal tumors (GIST) by revealing biologic
changes such as how the tumor processes the fuel that makes it grow,
but CT can indirectly reveal biologic changes as well by analyzing the
tumor's density, say researchers from The University of Texas M. D.
Anderson Cancer Center in Houston.</p>
]]></description>
		<link>http://www.gistsupport.org/posts/tumor-size-alone-not-always-best-for-gauging-treatment-response31.php</link>
		<pubDate>Mon, 13 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/tumor-size-alone-not-always-best-for-gauging-treatment-response31.php</guid>
	</item>
	<item>
		<title><![CDATA[New point system enhances prognosis for GIST patients]]></title>
		<description><![CDATA[<p>Swedish researchers developed a method of predicting the probability GIST will recur after surgery.</p>
]]></description>
		<link>http://www.gistsupport.org/posts/new-point-system-enhances-prognosis-for-gist-patients28.php</link>
		<pubDate>Mon, 13 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/new-point-system-enhances-prognosis-for-gist-patients28.php</guid>
	</item>
	<item>
		<title><![CDATA[ Gastrointestinal Stromal Tumours: a report by B. Landuyt & AT Van Oosterom]]></title>
		<description><![CDATA[<br /><a href="http://www.bbriefings.com/pdf/1134/ACF1A71.pdf" target="_blank">&nbsp;</a>
]]></description>
		<link>http://www.gistsupport.org/posts/gastrointestinal-stromal-tumours-a-report-by-b.-landuyt-at-van-oosterom16.php</link>
		<pubDate>Mon, 13 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/gastrointestinal-stromal-tumours-a-report-by-b.-landuyt-at-van-oosterom16.php</guid>
	</item>
	<item>
		<title><![CDATA[patientINFORM]]></title>
		<description><![CDATA[This new service to summarize medical research for patients will be up and running soon.  
]]></description>
		<link>http://www.gistsupport.org/posts/patientinform13.php</link>
		<pubDate>Mon, 13 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/patientinform13.php</guid>
	</item>
	<item>
		<title><![CDATA[ Pfizer submits application to FDA for Sutent (SU11248)]]></title>
		<description><![CDATA[NEW YORK, August 10 -- Pfizer Inc said today that it has submitted a
New Drug Application for its cancer medicine SU11248 (sunitinib
malate), known as Sutent, to the U.S. Food and Drug Administration.
]]></description>
		<link>http://www.gistsupport.org/posts/pfizer-submits-application-to-fda-for-sutent-su1124812.php</link>
		<pubDate>Mon, 13 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/pfizer-submits-application-to-fda-for-sutent-su1124812.php</guid>
	</item>
	<item>
		<title><![CDATA[ECCO 13 - Sunitinib prolongs survival in GIST patients after imatinib mesylate failure]]></title>
		<description><![CDATA[This is a news story from Eurekalert concerning Sutent results
presented at the 13th European Cancer Conference, November 3, 2005.
]]></description>
		<link>http://www.gistsupport.org/posts/ecco-13--sunitinib-prolongs-survival-in-gist-patients-after-imatinib-mesylate-failure10.php</link>
		<pubDate>Mon, 13 Mar 2006</pubDate>
		<guid>http://www.gistsupport.org/posts/ecco-13--sunitinib-prolongs-survival-in-gist-patients-after-imatinib-mesylate-failure10.php</guid>
	</item>
	</channel>
</rss>